Zinger Key Points
- Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding.
- The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics for heart and reproductive conditions.
- China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the next trade alert free.
On Monday, Zomedica Corp. ZOM disclosed the launch of two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica’s progesterone test quantitatively measures progesterone levels in canine serum, helping determine optimal breeding timing, predict parturition dates, plan cesarean sections, and detect reproductive disorders, all with reference lab-level accuracy and in-clinic convenience.
The progesterone assay has become one of the most requested by practitioners, reflecting the high demand given the 4 million puppies born in the U.S. each year.
The canine NT-poBNP test measures NT-proBNP levels in EDTA plasma or serum, helping identify conditions such as congestive heart failure.
It distinguishes between cardiac and respiratory issues, identifies high-risk dogs, and supports monitoring of myxomatous mitral valve degeneration with reference lab-level accuracy.
Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica, said, “The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes.”
”This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients’ quality of life earlier in the disease process.”
“The TRUFORMA canine progesterone assay provides accurate serial quantitative progesterone measurements in clinic. This will permit veterinarians to recognize the optimal breeding window more efficiently, allowing for more successful breeding cycles.”
Ashley Wood, PhD, Zomedica’s Vice President of Research & Development added, “Canine NT-proBNP and progesterone expand the range of indications to now include cardiac and reproductive conditions, offering even more comprehensive insights and support for clinical decision-making.”
Last month, Zomedica launched its third equine-focused assay—insulin for equine plasma—on the TRUFORMA In-Clinic Biosensor Testing Platform.
Price Action: ZOM shares are down 4.31% at $0.1199 at the last check on Monday.
Read Next:
Image via Pexels
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
